<0> EBD GroupErin Righetti, +1 760-930-0500 </0>
The 18th annual BIO-Europe® international partnering conference will be held in Hamburg, Germany November 12–14, 2012 at the CCH Congress Center Hamburg. Europe’s largest partnering conference attracts the world’s top dealmakers from biotech, pharma and finance along with exciting emerging companies.
The event, organized by EBD Group, the leading partnering firm for the life science industry, will highlight the biotech and pharmaceutical community in the Hamburg and Schleswig-Holstein life science sector and the BioRegion comprised of Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway, Poland, Sweden, northern Germany and northwestern part of Russia.
The high caliber of the conference program is exemplified by the Monday business development track entitled “New Pharma Strategies: Refining the R&D Blueprint” that features a powerful lineup of experts weighing in on the changing blueprint of R&D and commercialization strategies. The session will be moderated by of Campbell Alliancewith panelists of Merck Serono; of AstraZeneca; and of the newly formed TransCelerate BioPharma collaborative.
“Partnering within R&D is improving discovery productivity and strengthening industry pipelines,” said of AstraZeneca. “However, more work is needed to operationalize innovative, collaborative structures among multiple players. Getting this right will benefit not only the entire drug development value chain, but most importantly, patients who need novel drugs.”
The presenting companies portion of the program gives venture capitalists and pharmaceutical companies a firsthand look at prominent new discovery pipelines taking shape in the market.
“Local and international companies are selected based on their innovative technologies and the opportunities available to potential partners. It is this innovation that will lead the future of drug development,” said , President of EBD Group.
There will be company presentations by emerging biotech companies, and many returning presenters such as 4SC AG; Addex Therapeutics; Ark Therapeutics; Cevec Pharmaceuticals GmbH; Curis Inc.; Medigene AG; and Scil Proteins GmbH.
Another focus of the company presentations is on next generation companies from academic technology transfer and commercialization groups as well as innovative young companies including: Algiax Pharmaceuticals GmbH; DCPrime; GNA Biosolutions; Verapido / HSG-IMIT; Johns Hopkins School of Medicine; Macquarie University; PharmAbcine, Inc; Soluventis; UroTiss GmbH; Ciloa; Delenex Therapeutics AG; Toleranzia AB; STAT-Diagnostica & Innovation; BioScience Slovakia s.r.o.; Acesion Pharma; PSites Pharma GmbH; Novadiscovery; Jagiellonian University; Inositec; and Vaxdyn, SL.
“We develop fully integrated molecular and immunoassay diagnostic systems for clinical applications. Our products will allow the testing and screening of microorganisms, genetic-based diseases, or other analytes in a precise and automated way,” said Jordi Carrera from STAT-Diagnostica. “We are excited to present at BIO-Europe to find new partners that can help us further develop our Near Patient Testing products for healthcare and critical care professionals. BIO-Europe presents an incomparable opportunity for us to reach a large number of potential investors and partners in the smallest amount of time.”
This year’s event is being held in collaboration with Norgenta, known also as “Life Science Nord,” the service agency of Hamburg and the Federal State of Schleswig-Holstein, and ScanBalt™ fmba, the BioRegion association comprised of health and life science based sectors in the Nordic and Baltic countries.
Global networking opportunities can begin before the conference starts by joining partnering360®, the open online network for life science dealmakers at . partnering360 helps delegates have a more productive experience leading up to Bio-Europe and will grow their partnering network.
Registration information for BIO-Europe can be found online at
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, , is also used as the partnering engine at numerous third-party events around the world, and is the open online community of life science dealmakers that enhances partnering experiences all year long. Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit
* per an article from Current Partnering [dot] com: